In a patient with gastro‑oesophageal reflux disease, erosive oesophagitis, or dyspepsia, should treatment begin with a proton‑pump inhibitor (PPI) alone or be combined with domperidone from the start?

Treatment of GERD, Erosive Oesophagitis, and Dyspepsia: PPI Monotherapy vs. PPI Plus Domperidone

Start with PPI monotherapy as first-line therapy; reserve the addition of domperidone only for patients with persistent regurgitation or delayed gastric emptying symptoms who have failed to respond adequately to PPI therapy alone.

Initial Treatment Strategy

Begin with standard-dose PPI monotherapy taken 30-60 minutes before the first meal of the day. 1, 2 This represents the evidence-based standard of care supported by major gastroenterology societies. PPIs achieve healing rates exceeding 90% in erosive oesophagitis and provide symptom resolution in close to 80% of patients. 3

Why PPI Monotherapy First?

• Guidelines universally recommend PPI monotherapy as initial therapy without mention of routine combination with prokinetics like domperidone. 1
• The American Gastroenterological Association's 2024 guidance on acid suppression therapy does not include prokinetic agents in first-line recommendations. 1
• PPIs are the most effective agents for healing erosive disease and controlling acid-related symptoms, with proven superiority over all other antisecretory medications. 3, 4

When to Consider Adding Domperidone

Add domperidone to PPI therapy only in specific clinical scenarios:

• Persistent troublesome regurgitation despite adequate PPI therapy (this suggests a motility component rather than pure acid suppression failure). 1
• Documented delayed gastric emptying contributing to reflux symptoms.
• After confirming adequate PPI dosing and compliance (standard dose taken correctly before meals for 4-8 weeks). 2, 4

Evidence for Combination Therapy

A 2022 meta-analysis of 11 randomized controlled trials (841 participants) found that PPI plus domperidone resulted in significantly greater reduction in global GERD symptoms compared to PPI monotherapy, with similar adverse event profiles. 5 However, this evidence must be contextualized:

• No major gastroenterology guidelines recommend routine combination therapy as initial treatment. 1
• The benefit appears most pronounced in patients with motility-related symptoms (regurgitation, bloating) rather than pure heartburn. 5
• Domperidone carries cardiac risks (QT prolongation) that require consideration, particularly in patients with cardiac comorbidities.

Treatment Algorithm by Disease Severity

Non-Erosive Reflux Disease (NERD)

• Start with once-daily standard-dose PPI monotherapy. 1, 4
• On-demand therapy is acceptable after initial symptom control is achieved. 1, 6
• Do not add domperidone unless persistent regurgitation occurs despite adequate acid suppression. 1

Mild Erosive Oesophagitis (LA Grade A-B)

• Once-daily standard-dose PPI monotherapy is sufficient. 1, 2, 4
• Continuous daily maintenance therapy is required after healing to prevent recurrence. 2, 4
• Consider domperidone addition only if regurgitation persists after 4-8 weeks of PPI therapy. 5

Moderate to Severe Erosive Oesophagitis (LA Grade C-D)

• Consider twice-daily PPI dosing if inadequate response to once-daily therapy after 2-4 weeks. 7, 4
• For severe esophagitis, twice-daily standard-dose PPI may be more beneficial than once-daily dosing. 4
• Continuous daily PPI maintenance is mandatory to prevent recurrence of erosive disease. 2
• Add domperidone only for persistent regurgitation despite optimized PPI therapy. 1, 5

Critical Pitfalls to Avoid

Do not routinely prescribe combination therapy as initial treatment. This increases costs, exposes patients to additional medication risks (including domperidone's cardiac effects), and lacks guideline support. 1

Do not add domperidone before optimizing PPI therapy. First ensure:

• Correct timing (30-60 minutes before meals). 1, 2
• Adequate duration (4-8 weeks for initial healing). 2, 4
• Appropriate dosing (consider twice-daily for severe disease). 4
• Patient compliance with therapy. 8

Do not use on-demand or intermittent PPI therapy in patients with documented erosive disease. This leads to unacceptably high recurrence rates; continuous daily dosing is required. 1, 2

Do not substitute H2-receptor antagonists for PPIs in erosive disease, as they are significantly less effective. 2, 3

Managing PPI-Refractory Symptoms

If symptoms persist despite 8 weeks of twice-daily PPI therapy:

1. Confirm diagnosis with pH-impedance monitoring to distinguish true refractory GERD from functional heartburn or esophageal hypersensitivity. 1, 8
2. Assess for non-acid reflux that may benefit from prokinetic therapy. 1, 5
3. Consider domperidone addition if regurgitation is the predominant persistent symptom. 1, 5
4. Evaluate for alternative diagnoses including eosinophilic esophagitis, achalasia, or functional disorders. 8

Up to 40% of GERD patients report partial or complete lack of response to standard-dose PPI, but this often reflects inadequate dosing, poor timing, or non-acid-related symptoms rather than true PPI resistance. 8

Practical Implementation

For typical GERD/erosive oesophagitis/dyspepsia:

• Prescribe omeprazole 20 mg or lansoprazole 30 mg once daily, 30-60 minutes before breakfast. 7
• Reassess at 4-8 weeks. 2, 4
• If inadequate response, increase to twice-daily dosing before adding other agents. 7, 4
• Reserve domperidone addition for persistent regurgitation after optimizing PPI therapy. 1, 5

Maintenance strategy:

• Continuous daily PPI for erosive disease (any grade). 2
• Lowest effective dose for symptom control in NERD. 1, 6
• Never attempt step-down in documented erosive disease. 2